Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2J2 | P51589 | 13/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.74 |
| ▸ | HRH1 | P35367 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11798280 | 0.88 | CYP2J2 (0.84) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL11793534 | 0.87 | CYP2J2 (1.00) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL11541690 | 0.87 | CYP2J2 (0.83) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL11795603 | 0.86 | CYP2J2 (0.98) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL2763481 | 0.86 | CYP2J2 (0.75) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL3949330 | 0.86 | CYP2J2 (0.78) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL17023784 | 0.86 | CYP2J2 (0.81) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Methane SCHEMBL6325016 | 0.85 | CYP2J2 (0.77) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL7621966 | 0.85 | CYP2J2 (0.81) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL11838580 | 0.85 | CYP2J2 (0.81) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091938-B1 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTISUB II INC (US) | 2010-10-20 | — | — | EP | disclosed |
| US-6930197-B2 | Antihistaminic piperidine derivatives and intermediates for the preparation thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-6730791-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-05-04 | — | — | US | disclosed |
| US-6700012-B2 | FOR THERAPY OF ALLERGIC DISORDERS | AVENTIS PHARMACEUTICALS INC. | 2004-03-02 | — | — | US | disclosed |
| US-6689898-B2 | FOR THERAPY OF ALLERGIES | AVENTIS PHARMACEUTICALS INC. | 2004-02-10 | — | — | US | disclosed |
| US-6683094-B2 | 4-(1-HYDROXY-4-(4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL)BUTYL) -ALPHA-(HYDROXYMETHYL)-ALPHA-METHYL-BENZENEACETIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. | 2004-01-27 | — | — | US | disclosed |
| US-6673933-B2 | 1-(3-(4-(1,1-BIS(ALKYOXYCARBONYL)ALKYL)PHENYL)CARBONYLPROPYL), 4-(HYDROXYDIPHENYLMETHYL)PIPERIDINE | AVENTIS PHARMACEUTICAL INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030022919-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-08-15 | — | — | US | disclosed |
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | CHATTEM INC. | 2002-07-25 | — | — | US | disclosed |
| EP-1091938-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001671-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099088-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH2, HRH1, HRH4 | CYP2J2 314/4885CYP3A4 207/4885CYP2C9 614/4885 |
| US-20020111513-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | CYP2J2 295/4885CYP3A4 190/4885CYP2C9 479/4885 |
| US-20020099077-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | CYP2J2 559/4885CYP3A4 432/4885CYP2C9 657/4885 |
| US-20030022919-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | CYP2J2 431/4885CYP3A4 299/4885CYP2C9 355/4885 |
| US-20020099091-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | CYP2J2 454/4885CYP3A4 329/4885CYP2C9 759/4885 |
| US-20020099090-A1 | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof | HRH1, HRH2, HRH4 | CYP2J2 276/4885CYP3A4 228/4885CYP2C9 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.